Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He leads a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology
Awards, Training and Qualifications
- MB BS University of London 1990
- DPhil University of Oxford 1998
- FRCP Royal College of Physicians, London 2006
MB BS, DPhil, FRCP
Head of Department and Professor of Motor Neuron Biology
The main aim of my research is to identify targets for therapy in motor neuron diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy. In particular, we use laboratory models including motor neurons from induced pluripotent stem cells from patients to understand why motor neuron integrity fails in the presence of certain genetic mutations (eg; TDP-43 or C9orf72 in ALS). We also use these models to identify drug targets. Our work takes place in the context of a larger team of researchers in Oxford interested in translational research in neurodegenerative diseases, and we have many national and international collaborations.
Professor Talbot is not currently accepting new DPhil students.
Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis
Thompson AG. et al, (2021), Journal of Neurology, Neurosurgery & Psychiatry
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers
Vahsen BF. et al, (2021), Nature Reviews Neurology
Isolated homozygous R217X OPTN mutation causes knock-out of functional C-terminal optineurin domains and associated oligodendrogliopathy-dominant ALS–TDP
Nolan M. et al, (2021), Journal of Neurology, Neurosurgery & Psychiatry
Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
Winkelsas AM. et al, (2021), Molecular Therapy - Nucleic Acids, 23, 731 - 742
A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS. et al, (2021), Cell Death Dis, 12